keyword
https://read.qxmd.com/read/38495878/deep-analysis-of-skin-molecular-heterogeneities-and-their-significance-on-the-precise-treatment-of-patients-with-psoriasis
#1
JOURNAL ARTICLE
Shengxiao Zhang, Minjing Chang, Leilei Zheng, Can Wang, Rong Zhao, Shan Song, Jiawei Hao, Lecong Zhang, Caihong Wang, Xiaofeng Li
BACKGROUND: Psoriasis is a highly heterogeneous autoinflammatory disease. At present, heterogeneity in disease has not been adequately translated into concrete treatment options. Our aim was to develop and verify a new stratification scheme that identifies the heterogeneity of psoriasis by the integration of large-scale transcriptomic profiles, thereby identifying patient subtypes and providing personalized treatment options whenever possible. METHODS: We performed functional enrichment and network analysis of upregulated differentially expressed genes using microarray datasets of lesional and non-lesional skin samples from 250 psoriatic patients...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38495872/identification-of-immunological-patterns-characterizing-immune-related-psoriasis-reactions-in-oncological-patients-in-therapy-with-anti-pd-1-checkpoint-inhibitors
#2
JOURNAL ARTICLE
Martina Morelli, Maria Luigia Carbone, Giovanni Luca Scaglione, Claudia Scarponi, Valentina Di Francesco, Sabatino Pallotta, Federica De Galitiis, Siavash Rahimi, Stefania Madonna, Cristina Maria Failla, Cristina Albanesi
INTRODUCTION: Immunotherapy with biologics targeting programmed cell death protein-1 (PD-1) is highly effective in the treatment of various malignancies. Nevertheless, it is frequently responsible for unexpected cutaneous manifestations, including psoriasis-like dermatitis. The pathogenesis of anti-PD-1-induced psoriasis has yet to be clarified, even though it is plausible that some innate and adaptive immunity processes are in common with canonical psoriasis. The genetic predisposition to psoriasis of patients could also be a contributing factor...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38482003/il-17a-inhibitors-alleviate-psoriasis-with-concomitant-restoration-of-intestinal-skin-microbiota-homeostasis-and-altered-microbiota-function
#3
JOURNAL ARTICLE
Huixia Zhao, Lili Shang, Yuting Zhang, Zhaojun Liang, Nan Wang, Qian Zhang, Chong Gao, Jing Luo
BACKGROUND: Disturbed gut microbiota and associated metabolic dysfunction exist in Psoriasis. Despite the growing use of interleukin-17 inhibitor (anti-IL17) therapy, the effect of anti-IL17 on gut/skin microbiota function is not fully understood in patients with Psoriasis. OBJECTIVE: Therefore, we explored whether Psoriasis is associated with alterations in selected gut/skin microbiota in a study cohort, and a longitudinal cohort study to reveal the effects of IL-17A inhibitor treatment on gut microbiota in Psoriasis...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38460894/understanding-the-pathogenic-significance-of-altered-calcium-calmodulin-signaling-in-t-cells-in-autoimmune-diseases
#4
REVIEW
Tomohiro Koga
Calcium/calmodulin-dependent protein kinase IV (CaMK4) serves as a pivotal mediator in the regulation of gene expression, influencing the activity of transcription factors within a variety of immune cells, including T cells. Altered CaMK4 signaling is implicated in autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis, which are characterized by dysregulated immune responses and clinical complexity. These conditions share common disturbances in immune cell functionality, cytokine production, and autoantibody generation, all of which are associated with disrupted calcium-calmodulin signaling...
March 7, 2024: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://read.qxmd.com/read/38454607/ankrd22-promotes-resolution-of-psoriasiform-skin-inflammation-by-antagonizing-nik-mediated-il-23-production
#5
JOURNAL ARTICLE
Xichun Xia, Leqing Zhu, Miaomiao Xu, Zhiwei Lei, Hai Yu, Guangqiang Li, Xiao Wang, Hongling Jia, Zhinan Yin, Fang Huang, Yunfei Gao
Inflammation resolution is an essential process for preventing the development of chronic inflammatory diseases. However, the mechanisms that regulate inflammation resolution in psoriasis are not well understood. Here, we report that ANKRD22 is an endogenous negative orchestrator of psoriasiform inflammation, as ANKRD22-deficient mice are more susceptible to IMQ-induced psoriasiform inflammation. Mechanistically, ANKRD22 deficiency leads to excessive activation of TNFRII-NIK-mediated noncanonical NF-κB signaling pathway, resulting in hyperproduction of IL-23 in DCs...
March 6, 2024: Molecular Therapy
https://read.qxmd.com/read/38436011/construction-and-validation-of-m6a-related-diagnostic-model-for-psoriasis
#6
JOURNAL ARTICLE
Jing Liu, Youlin Wang, Yu Sheng, Limin Cai, Yongchen Wang
BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory disease. N6-methyladenosine (m6A) is involved in numerous biological processes in both normal and diseased states. Herein, we aimed to explore the potential role of m6A regulators in the diagnosis of psoriasis and predict molecular mechanisms by which m6A regulators impact psoriasis. METHODS: GSE30999 (170 human skin tissue samples) and GSE13355 (180 human skin tissue samples) were downloaded as the training analysis dataset and validation dataset respectively...
2024: PeerJ
https://read.qxmd.com/read/38419497/rutaecarpine-ameliorates-imiquimod-induced-psoriasis-like-dermatitis-in-mice-associated-with-alterations-in-the-gut-microbiota
#7
JOURNAL ARTICLE
Yongjian Li, Zhengping Tan, Wencan Li, Zongxuan Li, Guiying Zhang
Psoriasis is accepted as a chronic, inflammatory, immune-mediated skin disease triggered by complex environmental and genetic factors. For a long time, disease recurrence, drug rejection, and high treatment costs have remained enormous challenges and burdens to patients and clinicians. Natural products with effective immunomodulatory and anti-inflammatory activities from medicinal plants have the potential to combat psoriasis and complications. Herein, an imiquimod (IMQ)-induced psoriasis-like dermatitis model is established in mice...
February 28, 2024: Acta Biochimica et Biophysica Sinica
https://read.qxmd.com/read/38402151/anti-psoriatic-characteristics-of-rocen-topical-arthrocen-in-comparison-with-cyclosporine-a-in-a-murine-model
#8
JOURNAL ARTICLE
Ramin Goudarzi, Min-Ho Kim, Alireza Partoazar
Topical ROCEN (Roc), liposomal arthrocen hydrogel, is a robust anti-inflammatory formulation which has been developed for skin diseases such as eczema. Therefore, we aimed to evaluate the efficacy of Roc 2% on the healing of imiquimod (Imiq)-induced psoriasis in a mouse model. Psoriasis was induced by applying Imiq topically to the mice's back skin once daily for five consecutive days. Moreover, a group of animal experiments was treated with Cyclosporine A (CsA), as a standard drug, for comparison with Roc treated group...
February 24, 2024: BMC complementary medicine and therapies
https://read.qxmd.com/read/38375022/transcription-factor-irf7-is-involved-in-psoriasis-development-and-response-to-guselkumab-treatment
#9
JOURNAL ARTICLE
Xiuqing Yuan, Tiantian Xin, Huanhuan Yu, Jian Huang, Yaohan Xu, Caixin Ou, Yongfeng Chen
PURPOSE: Guselkumab is a highly effective biologic agent for treating psoriasis. This study aimed to explore potential transcription factors involved in psoriasis pathogenesis and response to guselkumab treatment, aiming to provide new therapeutic strategies for psoriasis. PATIENTS AND METHODS: We analyzed gene expression and single-cell RNA-seq data from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) that upregulated in psoriasis and downregulated after guselkumab treatment were subjected to enrichment analyses...
2024: Journal of Inflammation Research
https://read.qxmd.com/read/38372938/inhibition-of-receptor-interacting-protein-kinase%C3%A2-1-in-chronic-plaque-psoriasis-a-multicenter-randomized-double-blind-placebo-controlled-study
#10
JOURNAL ARTICLE
Valerie J Ludbrook, David C Budd, Katie Thorn, Debra Tompson, Bartholomew J Votta, Lucy Walker, Amy Lee, Xin Chen, Amanda Peppercorn, Wei Jing Loo
INTRODUCTION: Receptor-interacting protein kinase 1 (RIPK1), a key mediator of inflammation through necroptosis and proinflammatory cytokine production, may play a role in the pathogenesis of immune-mediated inflammatory diseases such as chronic plaque psoriasis. An experimental medicine study of RIPK1 inhibition with GSK2982772 immediate-release formulation at doses up to 60 mg three times daily in mild to moderate plaque psoriasis indicated that efficacy may be improved with higher trough concentrations of GSK2982772...
February 19, 2024: Dermatology and Therapy
https://read.qxmd.com/read/38291032/single-cell-analysis-of-psoriasis-resolution-demonstrates-an-inflammatory-fibroblast-state-targeted-by-il-23-blockade
#11
JOURNAL ARTICLE
Luc Francis, Daniel McCluskey, Clarisse Ganier, Treasa Jiang, Xinyi Du-Harpur, Jeyrroy Gabriel, Pawan Dhami, Yogesh Kamra, Sudha Visvanathan, Jonathan N Barker, Catherine H Smith, Francesca Capon, Satveer K Mahil
Biologic therapies targeting the IL-23/IL-17 axis have transformed the treatment of psoriasis. However, the early mechanisms of action of these drugs remain poorly understood. Here, we perform longitudinal single-cell RNA-sequencing in affected individuals receiving IL-23 inhibitor therapy. By profiling skin at baseline, day 3 and day 14 of treatment, we demonstrate that IL-23 blockade causes marked gene expression shifts, with fibroblast and myeloid populations displaying the most extensive changes at day 3...
January 30, 2024: Nature Communications
https://read.qxmd.com/read/38284189/association-between-several-immune-response-related-genes-and-the-effectiveness-of-biological-treatments-in-patients-with-moderate-to-severe-psoriasis
#12
JOURNAL ARTICLE
Alba Loras, Marta Gil-Barrachina, Barbara Hernando, Gemma Perez-Pastor, Alvaro Martinez-Domenech, Laura Mahiques, Gerard Pitarch, Francisca Valcuende-Cavero, Rosa Ballester-Sanchez, Maria Angeles Marques-Torrejon, Conrado Martinez-Cadenas
Biological therapies are safer and more effective against psoriasis than conventional treatments. Even so, 30-50% of psoriatic patients show an inadequate response, which is associated with individual genetic heterogeneity. Pharmacogenetic studies have identified several single nucleotide polymorphisms (SNPs) as possible predictive and prognostic biomarkers for psoriasis treatment response. The objective of this study was to determine the link between several SNPs and the clinical response to biological therapies in patients with moderate-severe psoriasis...
January 2024: Experimental Dermatology
https://read.qxmd.com/read/38271532/spesolimab-a-novel-interleukin-36-inhibitor-for-generalized-pustular-psoriasis-flares-in-adult-patients
#13
JOURNAL ARTICLE
Tuba Bukhari, Mariya Markovina, Abrahim Abduelmula, Brian D Rankin, Ronald Vender, Jensen Yeung, Alim R Devani, Vimal H Prajapati
Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flares, as demonstrated in clinical trials...
January 2024: Skin Therapy Letter
https://read.qxmd.com/read/38095377/activation-and-upregulation-of-keratinocyte-and-epidermal-transglutaminases-are-associated-with-depletion-of-their-substrates-in-psoriatic-lesions
#14
JOURNAL ARTICLE
N S Alharbi, I S Almami
OBJECTIVE: Psoriasis is a chronic skin disorder caused by abnormal interactions between epidermal and immune cells. Thus, the interplay between the proliferation and differentiation of epidermal components should be tightly regulated to protect against psoriasis. The differentiation process is primarily controlled by transglutaminases (TGs). However, studies on TG enzymes and their molecular alterations in psoriatic skin lesions are limited. Therefore, this study aimed to investigate TG activity and gene and protein expression in human psoriatic and normal skin tissues...
December 2023: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38086352/genetic-studies-of-actinic-keratosis-development-where-are-we-now
#15
REVIEW
Young Bok Lee, Jong-Il Kim
Actinic keratosis (AK) is a common precancerous skin lesion that can develop into cutaneous squamous cell carcinoma (CSCC). AK is characterized by atypical keratinocytes in the skin's outer layer and is commonly found in sun-exposed areas. Like many precancerous lesions, the development of AK is closely associated with genetic mutations. The molecular biology and transcriptional mechanisms underlying AK development are not well understood. Ultraviolet (UV) light exposure, especially UVA and UVB radiation, is a significant risk factor for AK, causing DNA damage and mutagenic effects...
December 2023: Annals of Dermatology
https://read.qxmd.com/read/38059657/hydroxychloroquine-exacerbates-imiquimod-induced-psoriasis-like-dermatitis-through-stimulating-overexpression-of-il-6-in-keratinocytes
#16
JOURNAL ARTICLE
Ling-Jung Yen, Ying-Chin Chen, Kai-Chun Wang, Meng-Chieh Shih, Chia-Ling Li, Sheng-Jie Yu, Ling-Ying Lu
Objective Hydroxychloroquine (HCQ) is a US Food and Drug Administration (FDA)-approved treatment for systemic lupus erythematosus (SLE) through inhibition of antigen presentation and subsequent reduction in T cell activation. Psoriasis relapse after antimalarial therapy have been reported in up to 18% of patients with psoriasis. Here, we explored the role of HCQ on exacerbating dermatitis utilizing an imiquimod (IMQ)-induced psoriasis-like dermatitis mouse model. Methods Thirty-six C57BL/6 female mice were divided into six groups: wild-type control, IMQ-Only, pre-treat HCQ (30 mg/kg and 60 mg/kg HCQ), and co-treat HCQ with IMQ (30 mg/kg and 60 mg/kg HCQ)...
December 7, 2023: Immunopharmacology and Immunotoxicology
https://read.qxmd.com/read/38028419/influence-of-adalimumab-on-interleukin-12-23-signalling-pathways-in-human-keratinocytes-treated-with-lipopolysaccharide-a
#17
JOURNAL ARTICLE
Paulina Buda, Piotr Michalski, Oliwia Warmusz, Anna Michalska-Bańkowska, Tomasz Sirek, Piotr Ossowski, Paweł Bogdał, Damian Strojny, Anna Pisany-Syska, Beniamin Oskar Grabarek
INTRODUCTION: The interleukin-12/23 (IL-12/23) signalling pathway plays an important role in the pathogenesis of psoriasis. In addition, even molecularly targeted therapy has been reported to lose adequate response to treatment. AIM: To determine the expression patterns of mRNAs and miRNAs related to IL-12/23 signalling pathways in the human keratinocyte culture exposed to liposaccharide A (LPS) and then adalimumab in comparison with untreated cells. MATERIAL AND METHODS: Human, adult, low-Calcium, high-Temperature keratinocyte (HaCaT) cultures were exposed to 1 µg/ml LPS for 8 h, and then adalimumab was added to the cultures at a concentration of 8 µg/ml and incubated for 2, 8, and 24 h...
October 2023: Postȩpy Dermatologii i Alergologii
https://read.qxmd.com/read/38013380/acute-generalized-exanthematous-pustulosis-caused-by-hydroxychloroquine-in-a-patient-with-rheumatoid-arthritis-and-card14-mutation-case-report
#18
JOURNAL ARTICLE
Feng Luo, Xue-Mei Yuan, Hong Xiong, Chang-Ming Chen, Wu-Kai Ma, Xue-Ming Yao
RATIONALE: Acute generalized exanthematous pustulosis (AGEP) is a serious adverse skin reaction characterized by the rapid appearance of densely distributed, small, sterile pustules with erythema. However, its pathogenesis is not fully understood. Hydroxychloroquine is widely used for the treatment of autoimmune diseases. Some patients presenting with AGEP have IL36RN and CARD14 gene mutations. Our report describes a patient with rheumatoid arthritis and AGEP associated with hydroxychloroquine and a newly discovered CARD14 gene mutation...
November 24, 2023: Medicine (Baltimore)
https://read.qxmd.com/read/38012097/comparative-study-on-gene-expression-in-psoriatic-lesions-versus-chronic-wound-healing-processes
#19
JOURNAL ARTICLE
Zhang Qiong, Fu Dongxue, Zhang Qing, Ren Yukun, An Yuepeng
Psoriasis and chronic ulcers not only significantly impair quality of life but also pose a challenge in dermatological treatment. This study aimed to identify new therapeutic targets and biomarkers for psoriasis and chronic ulcers by comparing their gene expression profiles. The gene expression profiles of psoriatic, wound and chronic ulcer patients, as well as healthy controls, were determined via RNA extraction and next-generation sequencing of biopsies. In order to identify biomarkers, functional enrichment, differential expression analysis and machine learning algorithms were implemented...
November 27, 2023: International Wound Journal
https://read.qxmd.com/read/37991693/efficacy-and-safety-of-candidate-biosimilar-ct-p43-versus-originator-ustekinumab-in-moderate-to-severe-plaque-psoriasis-28-week-results-of-a-randomised-active-controlled-double-blind-phase-iii-study
#20
JOURNAL ARTICLE
Kim A Papp, Mark G Lebwohl, Diamant Thaçi, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek C Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Tina Pyo, Woori Ko
BACKGROUND: CT-P43 is a candidate ustekinumab biosimilar in clinical development. OBJECTIVES: This paper aims to demonstrate equivalent efficacy of CT-P43 to originator ustekinumab in adults with moderate to severe plaque psoriasis. METHODS: This double-blind, phase III trial randomised patients (1:1) to receive subcutaneous CT-P43 or originator ustekinumab (45/90 mg for patients with baseline body weight ≤ 100 kg/> 100 kg) at week 0 and week 4 in Treatment Period I...
November 22, 2023: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
keyword
keyword
49866
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.